Morning Briefing
Summaries of health policy coverage from major news organizations
UNITAID Concerned About Infant HIV Medication Shortage, Drug Company Says Supply Is Sufficient
Bristol-Myers Squibb's plans this month to close its plant in Meymac, France, that manufactures "the last therapeutic option" for HIV-positive babies has drawn criticism from UNITAID, Reuters reports. In an open letter published in the Lancet (.pdf), UNITAID writes that "[c]losing this factory means that 4,000 to 7,000 babies currently enrolled in treatment plans in developing countries through UNITAID could be left without the medicines they need."
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
